Press releases & news
Poster presentation at ESMO 2018 in Munich
2cureX AB (“2cureX”) hereby announces that one of its clinical partners, Vejle Hospital presented a poster at the ESMO (European...
2cureX CEO-Interview Ole Thastrup CE-IVD status IndiTreat® and 2cureX commercial outlook
Last week, 2cureX took a big step towards market launch of IndiTreat by obtaining CE-IVD labelling of the product. Below,...
Article from BioStock
BioStock article about CE-IVD certification. The article is in Swedish. Read it here
2cureX presented on Sedermera Day, 11th October in Gothenburg
CEO Ole Thastrup and CBO Maarten van der Linden presented 2cureX, including the Breaking News that 2cureX has obtained CE-IVD...
Supplementary information concerning the newsletter ”2cureX German subsidiary receives contribution for the development of IndiTreat® tests in immuno-oncology”
2cureX AB published on 2018-10-03 a corporate news that the company’s German subsidiary 2cureX GmbH (”2cureX”) had received a grant...
2cureX German subsidiary receives contribution for the development of IndiTreat® tests in immuno-oncology
2cureX AB’s German subsidiary 2cureX GmbH (“2cureX”) has received funding from the German Federal Ministry of Education and Research to...
Laboratory: 2cureX, Fruebjergvej 3, 2100 Copenhagen Ø, Denmark|
Phone: +45 2211 5399|